Jeremy M. Levin - 11 Dec 2025 Form 4 Insider Report for Ovid Therapeutics Inc. (OVID)

Reporting relationship: CEO, Director
Issuer ticker: OVID
Reported as of: 11 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Dec 2025, 16:15:07 UTC
Prior SEC filing: 24 Feb 2025
Next SEC filing: 02 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Jeremy Levin

Key filing fact

Jeremy M. Levin filed Form 4 for Ovid Therapeutics Inc. (OVID) on 18 Dec 2025.

Key facts

This page summarizes Jeremy M. Levin's Form 4 filing for Ovid Therapeutics Inc. (OVID).
5 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 18 Dec 2025, 16:15.

Change

Previous filing in this sequence was filed on 24 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001256153 Primary reporting owner

LEVIN JEREMY M

Relationship: CEO, Director
Address: C/O OVID THERAPEUTICS INC., 441 NINTH AVENUE, 14TH FLOOR, NEW YORK
Signature: /s/ Jeremy Levin
Signature date: 18 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OVID transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +71,000
Change %: +2%
Price
Shares after: 3,687,715
Date: 15 Dec 2025
Ownership: Direct
Footnotes: F1

OVID holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 35,461
Date: 11 Dec 2025
Ownership: See Footnote
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OVID transaction Derivative

Series B Convertible Preferred Stock

Purchase

Transaction value
Shares: +71
Change %
Price
Shares after: 71
Date: 11 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 71,000
Exercise price
Footnotes: F1, F3

OVID transaction Derivative

Series A Warrant (right to buy)

Purchase

Transaction value
Shares: +47,333
Change %
Price
Shares after: 47,333
Date: 11 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 47,333
Exercise price: $1.40
Footnotes: F3, F4, F5

OVID transaction Derivative

Series B Warrant (right to buy)

Purchase

Transaction value
Shares: +35,500
Change %
Price
Shares after: 35,500
Date: 11 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 35,500
Exercise price: $1.40
Footnotes: F3, F6

OVID transaction Derivative

Series B Convertible Preferred Stock

Conversion of derivative security

Transaction value: $0
Shares: -71
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 15 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 71,000
Exercise price
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Each share of Series B Convertible Preferred Stock automatically converted into 1,000 shares Common Stock at 5 p.m. Eastern Time on December 15, 2025, pursuant to the approval of the Issuer's Stockholders on December 11, 2025.

Footnote F2

The reportable securities are owned directly by Divo Holdings, LLC ("Divo"). The Reporting Person's spouse is the manager of Divo. The Reporting Person disclaims beneficial ownership of the shares held by Divo and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose.

Footnote F3

The reported securities are included within 71 investment units purchased by the Reporting Person for $1,400 per investment unit. Each investment unit consists of one share of Series B Convertible Preferred Stock, one Series A Warrant to purchase 666.66 shares of common stock, and one Series B Warrant to purchase 500 shares of common stock.

Footnote F4

Each Series A Warrant became immediately exercisable pursuant to the approval of the Issuer's Stockholders on December 11, 2025.

Footnote F5

The Series A Warrants will terminate upon the earlier of (a) the 30th calendar day following date on which we publicly announce the clearance of the first of any investigational new drug application, clinical trial application or other foreign equivalent with respect to the clinical development of our OV4071 product candidate; provided that such 30-calendar day period shall not commence unless and until a registration statement covering the resale of the shares of Common Stock issuable upon exercise of the Series A Warrants is effective; and (b) October 6, 2030.

Footnote F6

Each Series B Warrant became immediately exercisable pursuant to the approval of the Issuer's Stockholders on December 11, 2025.